[en] Objectives: To collect recent data on the susceptibility of anaerobes and to compare them with results from previous studies. Methods: Four hundred and forty-three anaerobic clinical isolates from various body sites were prospectively collected from October 2003 to February 2005 in nine Belgian hospitals. MICs were determined for nine anti-anaerobic and three recently developed antibiotics. Results: Most Gram-negative bacilli except Fusobacterium spp. were resistant to penicillin. Piperacillin/tazobactam, metronidazole, chloramphenicol, meropenem and amoxicillin/clavulanic acid were very active against all groups, but only 86% of Bacteroides fragilis group strains were susceptible to the latter. Cefoxitin, cefotetan and clindamycin were less active. In particular, only 62%, 52% and 48% of B. fragilis group strains were susceptible, respectively. Clindamycin shows a continuing decrease in activity, as 83% were still susceptible in 1987 and 66% in 1993-94. Anti-anaerobic activity of the new antibiotics is interesting, with MIC50 and MIC90 of 1 and > 32 mg/L for moxifloxacin, 2 and 4 mg/L for linezolid and 0.5 and 8 mg/L for tigecycline. Conclusions: The susceptibility of anaerobic bacteria remains stable in Belgium, except for clindamycin, which shows a continuous decrease in activity. However, for each of the tested antibiotics, at least a few resistant organisms were detected. Consequently, for severe infections involving anaerobic bacteria, it could be advisable to perform microbiological testing instead of relying on known susceptibility profiles. Periodically monitoring background susceptibility remains necessary to guide empirical therapy.
Hedberg M, Nord CE. ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003; 9: 475-88.
National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard M11-A6. NCCLS, Wayne, PA, USA, 2004.
Piérard D, De Meyer A, Rosseel P et al. In vitro activity of amoxycillin plus clavulanic acid and ticarcillin plus clavulanic acid compared with that of other antibiotics against anaerobic bacteria. Acta Clin Belg 1989; 44: 228-36.
Piérard D, De Meyer A, Rosseel P et al. In vitro activity of amoxicillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: Comparison with the results of the 1987 survey. Acta Clin Belg 1996; 51: 70-9.
Jousimies-Somer H, Summanen P, Citron DM et al. Anaerobic Bacteriology Manual, 6th edn. Belmont: Star Publishing Company, 2002.
Piérard D, De Meyer A, Rosseel P et al. Use of the Etest for determining antimicrobial susceptibility of anaerobic bacteria. Pathol Biol (Paris) 1996; 44: 358-62.
Société Française de Microbiologie. Comité de l'antibiogramme de la Société Française de Microbiologie. Communiqué 2005 (Edition de Janvier 2005). Paris Cedex, France: Société Française de Microbiologie, 2005.
European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Eucast definitive document E. Def 4.1. Linezolid breakpoints. Clin Microbiol Infect 2001; 7: 283-4.
Salonen JH, Eerola E, Meurman O. Clinical significance and outcome of anaerobic bacteremia. Clin Infect Dis 1998; 26: 1413-7.
Nguyen MH, Yu VL, Morris AJ et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: Findings of a multicenter prospective observational trial. Clin Infect Dis 2000; 30: 870-6.
Stevens DL, Laine BM, Mitten JE. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother 1987; 31: 312-6.
Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: A crossnational database study. Lancet 2005; 365: 579-87.